Marksans Pharma reported a consolidated net profit of ₹4,200.64 million for the year ended March 31, 2026, compared to ₹3,826.19 million in the prior year. Revenue from operations increased to ₹29,509.38 million from ₹26,228.45 million in FY25. The Board of Directors has recommended a final dividend of ₹0.90 per equity share for the financial year 2025-26.

The standalone net profit for the year stood at ₹3,006.98 million, up from ₹1,882.72 million in the previous year. Standalone revenue from operations grew to ₹13,414.76 million from ₹11,743.74 million. The financial results were audited by MSKA & Associates LLP, which expressed an unmodified opinion.

Consolidated Financial Performance

The company's total consolidated income for FY26 reached ₹30,334.71 million. Profit before tax for the year was ₹5,605.55 million, compared to ₹5,039.67 million in the previous year. The basic and diluted earnings per share for the year were recorded at ₹9.22, up from ₹8.40 in the prior year.

Segment and Subsidiary Updates

The Group operates a single reportable segment, Pharmaceuticals. During the year, the company incorporated two new wholly owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland and Marksans (Canada) Inc. in Canada. The consolidated financial statements include the results of 12 audited subsidiaries and 3 unaudited subsidiaries.

Key Developments and Provisions

The company implemented the New Labour Codes introduced by the Government of India, effective November 21, 2025. This resulted in a net impact of ₹26.09 million recognised as Employee Benefits Expense for the year ended March 31, 2026, following a reversal of ₹2.01 million during the quarter ended March 31, 2026.

The Board approved the Marksans Employees Stock Option Scheme 2024, granting 400,000 equity stock options to eligible employees on September 24, 2025. The total assets of the company stood at ₹38,609.02 million as of March 31, 2026, compared to ₹32,396.32 million in the previous year.

Marksans Pharma Ltd has completed the acquisition of 100% share capital of QliniQ B.V., a company based in the Netherlands. The transaction was finalized on June 16, 2026, as per the regulatory filing submitted to the National Stock Exchange of India Limited and BSE Limited. This acquisition marks a significant expansion of the company's operational reach in the European market.

The intimation was submitted under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously informed the exchanges about the proposed acquisition in a letter dated June 1, 2026. The completion of this process follows the necessary procedural approvals and due diligence.

Acquisition Details

The acquisition involves the purchase of the entire share capital of QliniQ B.V., thereby making it a wholly-owned subsidiary of Marksans Pharma Ltd. The financial details of the transaction were not disclosed in the regulatory filing. The move is expected to strengthen the company's presence in the Netherlands and broader European region.

Regulatory Compliance

The filing was signed by Harshavardhan Panigrahi, Company Secretary of Marksans Pharma Ltd. The intimation was submitted to ensure compliance with the SEBI regulations, requiring timely disclosure of material events. The company has requested the exchanges to take the intimation on record.

Strategic Implications

By acquiring QliniQ B.V., Marksans Pharma Ltd aims to leverage the Dutch company's capabilities to enhance its product offerings and market reach. The Netherlands serves as a strategic gateway to the European pharmaceutical market, known for its robust regulatory framework and high demand for quality healthcare products.